TRVI - NASDAQ
Trevi Therapeutics, Inc.
$13.45
-3.6%Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
At a Glance
Live SnapshotTrevi Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Trevi Therapeutics, Inc. Balance Sheet
TRVI • NASDAQ
| Trevi Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
ASSETS | ||||||||||
CURRENT ASSETS | ||||||||||
18.9M | 34.1M | 32.4M | 12.6M | 36.8M | 45M | 57.3M | 17.2M | 22M | 8.3M | |
169.3M | 73.5M | 50.6M | 107.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
188.3M | 107.6M | 83M | 120.5M | 36.8M | 45M | 57.3M | 17.2M | 22M | 8.3M | |
986K | 532K | 0.0 | 0.0 | 241K | 0.0 | 558K | 184K | 0.0 | 19K | |
0.0 | 0.0 | 0.0 | 0.0 | 241K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
986K | 532K | 0.0 | 0.0 | 0.0 | 0.0 | 558K | 184K | 0.0 | 19K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6M | 1.4M | 63K | 0.0 | |
0.0 | 939K | 3.6M | 795K | 886K | 1M | 1.7M | 1.4M | 93K | 87K | |
2.4M | 335K | 955K | 1.3M | 0.0 | 265K | -1.6M | 0.0 | 49K | 0.0 | |
191.7M | 109.4M | 87.5M | 122.6M | 38M | 46.3M | 59.6M | 18.8M | 22.2M | 8.4M | |
NON-CURRENT ASSETS | ||||||||||
855K | 1.2M | 1.6M | 194K | 184K | 330K | 430K | 149K | 14K | 5K | |
928K | 243K | 297K | 205K | 334K | 532K | 19K | 1.6M | 52K | 12K | |
1.8M | 1.5M | 1.9M | 399K | 518K | 862K | 449K | 1.7M | 66K | 17K | |
193.4M | 110.9M | 89.4M | 123M | 38.5M | 47.1M | 60M | 20.5M | 22.2M | 8.4M | |
LIABILITIES | ||||||||||
CURRENT LIABILITIES | ||||||||||
3.9M | 3.4M | 1.8M | 2.9M | 2.8M | 2M | 1.6M | 603K | 537K | 445K | |
3.9M | 3.4M | 1.8M | 2.9M | 2.8M | 2M | 1.6M | 603K | 537K | 445K | |
0.0 | 4.3M | 2.1M | 3.5M | 3.8M | 3.4M | 776K | 2.1M | 1.3M | 48K | |
307K | 0.0 | 0.0 | 7M | 5.8M | 0.0 | 99K | 0.0 | 5.3M | 17M | |
0.0 | 285K | 306K | 25K | 120K | 113K | 99K | 0.0 | 0.0 | 0.0 | |
5.5M | 2.5M | 1.6M | 0.0 | 114K | 0.0 | 2.6M | 0.0 | 0.0 | 2.9M | |
9.7M | 10.5M | 5.8M | 13.4M | 12.7M | 5.6M | 5.2M | 2.7M | 7.1M | 20.4M | |
NON-CURRENT LIABILITIES | ||||||||||
0.0 | 0.0 | 0.0 | 2.2M | 8.7M | 14M | 0.0 | 1.1M | 0.0 | 5.1M | |
0.0 | 0.0 | 0.0 | 3K | 0.0 | 196K | 0.0 | 460K | 325K | 310K | |
446K | 747K | 1M | 2.2M | 8.7M | 14.3M | 257K | 506K | 325K | 5.4M | |
446K | 1M | 1.3M | 27K | 144K | 257K | 356K | 46K | 0.0 | 0.0 | |
10.2M | 11.3M | 6.9M | 15.6M | 21.4M | 19.8M | 5.5M | 3.2M | 7.5M | 25.8M | |
SHAREHOLDERS' EQUITY | ||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 60M | 115.7M | 99.2M | 54.7M | |
128K | 94K | 68K | 60K | 29K | 19K | 18K | 101K | 4K | 4K | |
512.8M | 386.5M | 321.6M | 317.6M | 198M | 174.2M | 168.7M | 0.0 | 0.0 | 0.0 | |
-329.8M | -287M | -239.1M | -210.1M | -180.9M | -147M | -114.2M | -109.5M | -84.4M | -72.2M | |
148K | 61K | -29K | -122K | 0.0 | 0.0 | -60M | -46K | -23K | 0.0 | |
183.2M | 99.6M | 82.5M | 107.5M | 17.1M | 27.3M | 54.5M | 17.3M | 14.8M | -17.4M | |
183.2M | 99.6M | 82.5M | 107.5M | 17.1M | 27.3M | 54.5M | 17.3M | 14.8M | -17.4M | |
SUMMARY | ||||||||||
193.4M | 110.9M | 89.4M | 123M | 38.5M | 47.1M | 60M | 20.5M | 22.2M | 8.4M | |
169.3M | 73.5M | 50.6M | 107.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
753K | 1M | 1.3M | 9.2M | 14.6M | 14.2M | 356K | 1.1M | 5.3M | 22.1M | |
-18.2M | -33.1M | -31.1M | -3.4M | -22.2M | -30.8M | -57M | -16.1M | -16.7M | 13.8M | |
121,776,855 | 121,776,855 | 121,776,855 | 121,776,855 | 121,776,855 | 121,776,855 | 121,776,855 | 121,776,855 | 121,776,855 | 121,776,855 |
SEC Filings
TRVI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 05, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 17, 2026 | April 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 05, 2025 | December 01, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TRVI research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.